Cargando…

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

BACKGROUND: Increased evidences show that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) compared with cytotoxic chemotherapy for metastatic lung nonsquamous cell carcinoma harboring susceptible EGFR mutation, and ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chih-Jen, Tsai, Ming-Ju, Hung, Jen-Yu, Liu, Ta-Chih, Chou, Shah-Hwa, Lee, Jui-Ying, Hsu, Jui-Sheng, Tsai, Ying-Ming, Huang, Ming-Shyan, Chong, Inn-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803239/ https://www.ncbi.nlm.nih.gov/pubmed/27051298 http://dx.doi.org/10.2147/OTT.S100164

Ejemplares similares

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
por: Yang, Chih-Jen, et al.
Publicado: (2016)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study
por: Wang, Rui, et al.
Publicado: (2022)

The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations
por: Kuo, Chia-Yu, et al.
Publicado: (2019)

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study [Retraction]
Publicado: (2022)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
por: Kuo, Chia-Yu, et al.
Publicado: (2022)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Transplant Recipients Using Tacrolimus Had Higher Utilization of Healthcare Services Than Those Receiving Cyclosporine in Taiwan
por: Lin, Yi-Chang, et al.
Publicado: (2019)

Acute respiratory distress syndrome and acute myocarditis developed in a previously healthy adult with influenza B
por: Chang, Hsu-Liang, et al.
Publicado: (2016)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
por: Lin, Liping, et al.
Publicado: (2016)

A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma
por: Jan, Yi-Hua, et al.
Publicado: (2019)

Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli
por: Hsu, Jui-Feng, et al.
Publicado: (2015)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
por: Tsai, Ming-Ju, et al.
Publicado: (2023)

Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
por: Chang, Chia‐Hao, et al.
Publicado: (2017)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2016)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Convex border of peripheral non-small cell lung cancer on CT images as a potential indicator of pleural invasion
por: Hsu, Jui-Sheng, et al.
Publicado: (2017)

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Hsu, Chia-Chi, et al.
Publicado: (2021)

The Impact of Emergency Department Arrival Time on Door-to-Balloon Time in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention
por: Hsiao, Yu-Ting, et al.
Publicado: (2023)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

The impact of inappropriate antibiotics on bacteremia patients in a community hospital in Taiwan: an emphasis on the impact of referral information for cases from a hospital affiliated nursing home
por: Yang, Chih-Jen, et al.
Publicado: (2013)

Erectile Dysfunction in Patients with Sleep Apnea – A Nationwide Population-Based Study
por: Chen, Chia-Min, et al.
Publicado: (2015)

Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer
por: Yang, Chih-Jen, et al.
Publicado: (2015)

Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy
por: Lee, Jen-Yi, et al.
Publicado: (2011)

Endosomal Arl4A attenuates EGFR degradation by binding to the ESCRT-II component VPS36
por: Lin, Shin-Jin, et al.
Publicado: (2023)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_15rnmhoeenovdvqqluj2ernvrb